Each year, PDL reviews data reported by members, and reflects on the challenges pharmacists have faced, while extracting insights from the patterns/trends that emerged. Below are the top 10 most reported medicines in the 2024-2025 financial year: Oxycodone (immediate and slow release, individually and in combination) Semaglutide Tapentadol Methylphenidate Prednisone/olone Tirzepatide Oestrogen (oral and patches, individually and in combination but excludes oral contraceptives) Lisdexamfetamine Paracetamol and codeine combinations Levothyroxine The PDL Prof…

Member only access

This content is available to PDL members only.
To continue reading please log in to the member portal or join PDL today.

Share this article

Related Practice Alerts

Professional Indemnity cover for pharmacy students
21 April 2026
NationalIncident managementRegulatory and compliancePractice support, tips and tools
Learn more
Communication matters
16 April 2026
NationalNSWLeadership and communicationIncident managementPractice support, tips and tools
Learn more
Professional Indemnity Insurance – what hospital pharmacists need to know
1 April 2026
National
Learn more

It's time to renew your PDL membership for the year ahead.

Renew your PDL membership now and take a moment to review your Practice Profile, as updates have been made to our areas of practice. You can log in to the member portal using your email address or mobile number.